Consistent with our findings, PLK1 inhibitors were shown to exhibit a synergistic effect with conventional chemotherapy drugs in various cancer types, suggesting the potential therapeutic value of PLK1 inhibitors to reverse chemoresistance in CRC treatment.[34, 35, 36]. The gene discussed is PLK1; the disease is colorectal carcinoma.